Investigational drug · Phase 2
GEn-1124
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Respiratory Distress Syndrome, Acute.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "GEn-1124"
First trial start
2023
Apr 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GEn-1124", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Distress Syndrome, Acute
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "GEn-1124" as an intervention, largest first.
GEn1E LifesciencesIndustry
NCT05795465 · 52 participants (planned) · Start Apr 4, 2023 · Primary completion Oct 2026
Drug: GEn-1124; Placebo · For: Respiratory Distress Syndrome, Acute
Sites: Washington D.C., District of Columbia; Kansas City, Kansas; Baltimore, Maryland · 11 sites in all
- A Study to Assess the Pharmacokinetics of GEn-1124 After Single Oral Dosing in Healthy SubjectsCompleted
GEn1E LifesciencesIndustry
NCT07185113 · 6 participants · Start Oct 29, 2025 · Primary completion Nov 4, 2025
Drug: GEn-1124 · For: Healthy Adult Male
Sites: Christchurch, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
- First-in-class mitogen-activated protein kinase (MAPK) p38α: MAPK-activated protein kinase 2 dual signal modulator with anti-inflammatory and endothelial-stabilizing properties.
Tulapurkar ME, Shirey KA, Lugkey K, et al. · J Pharmacol Exp Ther 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.